Search Results - "GOOIJER, C"

First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma? by Douma, L.H., Baas, P., de Gooijer, C.J.

Get full text

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2 by de Gooijer, Mark C., de Vries, Nienke A., Buckle, Tessa, Buil, Levi C.M., Beijnen, Jos H., Boogerd, Willem, van Tellingen, Olaf

“…The anticancer drug temozolomide is the only drug with proven activity against high-grade gliomas and has therefore become a part of the standard treatment of…”
Get full text

The impact of P‐glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors by de Gooijer, Mark C., Zhang, Ping, Weijer, Ruud, Buil, Levi C.M., Beijnen, Jos H., van Tellingen, Olaf

“…Mitogen/extracellular signal‐regulated kinase (MEK) inhibitors have been tested in clinical trials for treatment of intracranial neoplasms, including…”
Get full text

PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models by Lin, Fan, de Gooijer, Mark C, Hanekamp, Diana, Chandrasekaran, Gayathri, Buil, Levi C M, Thota, Nishita, Sparidans, Rolf W, Beijnen, Jos H, Würdinger, Tom, van Tellingen, Olaf

“…The PI3K-AKT-mTOR signaling pathway is frequently activated in glioblastoma and offers several druggable targets. However, clinical efficacy of PI3K/mTOR…”
Get full text

ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy by FAN LIN, DE GOOIJER, Mark C, ROIG, Eloy Moreno, BUIL, Levi C. M, CHRISTNER, Susan M, BEUMER, Jan H, WÜRDINGER, Thomas, BEIJNEN, Jos H, VAN TELLINGEN, Olaf

“…Little is known about the optimal clinical use of ABT-888 (veliparib) for treatment of glioblastoma. ABT-888 is a PARP inhibitor undergoing extensive clinical…”
Get full text

Buparlisib is a brain penetrable pan-PI3K inhibitor by de Gooijer, Mark C., Zhang, Ping, Buil, Levi C. M., Çitirikkaya, Ceren H., Thota, Nishita, Beijnen, Jos H., van Tellingen, Olaf

“…Characterization of the genomic landscapes of intracranial tumours has revealed a clear role for the PI3K-AKT-mTOR pathway in tumorigenesis and tumour…”
Get full text

Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma by Dumoulin, D W, Douma, L H, Hofman, M M, van der Noort, V, Cornelissen, R, de Gooijer, C J, Burgers, J A, Aerts, J G J V

“…Nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) is a new first-line treatment combination for patients with pleural mesothelioma. Nivolumab-ipilimumab…”
Get full text

Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness by Pencheva, Nora, de Gooijer, Mark C., Vis, Daniel J., Wessels, Lodewyk F.A., Würdinger, Tom, van Tellingen, Olaf, Bernards, René

“…Diffuse and uncontrollable brain invasion is a hallmark of glioblastoma (GBM), but its mechanism is understood poorly. We developed a 3D ex vivo organotypic…”
Get full text

P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib by de Gooijer, Mark C., Zhang, Ping, Thota, Nishita, Mayayo-Peralta, Isabel, Buil, Levi C. M., Beijnen, Jos H., van Tellingen, Olaf

“…Summary Introduction Palbociclib is a cyclin dependent kinase (CDK) 4/6 inhibitor with nanomolar potency and was recently approved for treatment of breast…”
Get full text

ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost by de Gooijer, Mark C., Kemper, E. Marleen, Buil, Levi C.M., Çitirikkaya, Ceren H., Buckle, Tessa, Beijnen, Jos H., van Tellingen, Olaf

“…The impact of a compromised blood-brain barrier (BBB) on the drug treatment of intracranial tumors remains controversial. We characterize the BBB integrity in…”
Get full text

ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain by Lentzas, Aristeidis, de Gooijer, Mark C, Zuidema, Stefanie, Meurs, Amber, Çitirikkaya, Ceren H, Venekamp, Nikkie, Beijnen, Jos H, van Tellingen, Olaf

“…Pharmacotherapy for brain diseases is severely compromised by the blood-brain barrier (BBB). ABCB1 and ABCG2 are drug transporters that restrict drug entry…”
Get full text

Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8 by Berenguer, Jordi, Lagerweij, Tonny, Zhao, Xi Wen, Dusoswa, Sophie, van der Stoop, Petra, Westerman, Bart, Gooijer, Mark C. de, Zoetemelk, Marloes, Zomer, Anoek, Crommentuijn, Matheus H. W., Wedekind, Laurine E., López-López, Àlan, Giovanazzi, Alberta, Bruch-Oms, Marina, Meulen-Muileman, Ida H. van der, Reijmers, Rogier M., van Kuppevelt, Toin H., García-Vallejo, Juan-Jesús, van Kooyk, Yvette, Tannous, Bakhos A., Wesseling, Pieter, Koppers-Lalic, Danijela, Vandertop, W. Peter, Noske, David P., van Beusechem, Victor W., van Rheenen, Jacco, Pegtel, D. Michiel, Tellingen, Olaf van, Wurdinger, Thomas

“…Cancer cells release extracellular vesicles (EVs) that contain functional biomolecules such as RNA and proteins. EVs are transferred to recipient cancer cells…”
Get full text

Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype by Teng, Jian, Hejazi, Seyedali, Hiddingh, Lotte, Carvalho, Litia, de Gooijer, Mark C, Wakimoto, Hiroaki, Barazas, Marco, Tannous, Marie, Chi, Andrew S, Noske, David P, Wesseling, Pieter, Wurdinger, Thomas, Batchelor, Tracy T, Tannous, Bakhos A

“…Glioblastoma (GBM) is the most common and most aggressive primary malignant brain tumor. Standard-of-care treatment involves maximal surgical resection of the…”
Get full text

The G2 checkpoint—a node‐based molecular switch by Gooijer, Mark C., Top, Arnout, Bockaj, Irena, Beijnen, Jos H., Würdinger, Thomas, Tellingen, Olaf

“…Tight regulation of the eukaryotic cell cycle is paramount to ensure genomic integrity throughout life. Cell cycle checkpoints are present in each phase of the…”
Get full text

ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors by de Gooijer, Mark C., Buil, Levi C. M., Beijnen, Jos H., van Tellingen, Olaf

“…Summary Introduction Wee1 is an important kinase involved in the G2 cell cycle checkpoint and frequently upregulated in intracranial neoplasms such as…”
Get full text

Protocol for live-cell imaging during Tumor Treating Fields treatment with Inovitro Live by Slangen, Paul L.G., Porat, Yaara, Mertz, Marjolijn, van den Broek, Bram, Jalink, Kees, de Gooijer, Mark C., van Tellingen, Olaf, Borst, Gerben R.

“…Tumor Treating Fields (TTFields) are an FDA-approved anticancer treatment using alternating electric fields. Here, we present a protocol to perform live-cell…”
Get full text

Liquid-phase and evanescent-wave cavity ring-down spectroscopy in analytical chemistry by van der Sneppen, L, Ariese, F, Gooijer, C, Ubachs, W

“…Due to its simplicity, versatility, and straightforward interpretation into absolute concentrations, molecular absorbance detection is widely used in…”
Get full text

Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors by Metselaar, Dennis S., Meel, Michaël H., Goulding, Joshua R., du Chatinier, Aimeé, Rigamonti, Leyla, Waranecki, Piotr, Geisemeyer, Neal, de Gooijer, Mark C., Breur, Marjolein, Koster, Jan, Veldhuijzen van Zanten, Sophie E.M., Bugiani, Marianna, Franke, Niels E., Reddy, Alyssa, Wesseling, Pieter, Kaspers, Gertjan J.L., Hulleman, Esther

“…Atypical teratoid/rhabdoid tumors (ATRTs) are highly malignant embryonal tumors of the central nervous system with a dismal prognosis. Using a newly developed…”
Get full text

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC by Jebbink, M., de Langen, A.J., Monkhorst, K., Boelens, M.C., van den Broek, D., van der Noort, V., de Gooijer, C.J., Mahn, M., van der Wekken, A.J., Hendriks, L., Hashemi, S.M.S., Paats, M.S., Dingemans, A.C., Smit, E.F.

“…EGFR tyrosine kinase inhibitor improved the survival of patients with metastatic EGFR mutation-positive (EGFRm+) NSCLC. Despite high response rates, resistance…”
Get full text

An Experimenter’s Guide to Glioblastoma Invasion Pathways by de Gooijer, Mark C., Guillén Navarro, Miriam, Bernards, Rene, Wurdinger, Thomas, van Tellingen, Olaf

“…Glioblastoma is a highly aggressive brain tumor that is characterized by its unparalleled invasiveness. Invasive glioblastoma cells not only escape surgery and…”
Get full text